Summary So many shoutouts in this episode of Melanoma Matters! Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib trials, and discuss side effects associated with this class of therapy. Sapna clears her own confusion regarding the PDUFA date for the NEMO study, and James objects to the way the NEMO abbreviation was derived. Keywords targeted therapy, MEK inhibitors, METRIC, NEMO, pimasertib, NRAS, BRAF, melanoma, oncology, side effects, clinical trials...
इस एपिसोड का ट्रांसक्रिप्ट अभी तैयार नहीं है
आप इसे फिर भी प्लेयर में सुन सकते हैं। जिन एपिसोड का ट्रांसक्रिप्ट है, उनमें किसी भी शब्द पर टैप करके अर्थ देख सकते हैं।
